Technical Analysis for VYNE - VYNE Therapeutics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 3.30% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 3.30% | |
| NR7 | Range Contraction | 3.30% | |
| Stochastic Reached Oversold | Weakness | 3.30% | |
| Inside Day | Range Contraction | 3.30% | |
| Wide Bands | Range Expansion | 3.30% |
| Alert | Time |
|---|---|
| 20 DMA Resistance | about 20 hours ago |
| Rose Above 20 DMA | about 20 hours ago |
| 60 Minute Opening Range Breakout | about 20 hours ago |
| Up 5% | about 20 hours ago |
| 60 Minute Opening Range Breakdown | about 21 hours ago |
Get a Trading Assistant
- Earnings date: 11/11/2024
VYNE Therapeutics Inc. Description
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. It offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. The company is also developing FMX103, which is in Phase III clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and FCD105, a topical combination foam that is in Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris. In addition, it is developing Serlopitant, a once-daily oral NK1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is headquartered in Bridgewater, New Jersey.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Autoimmune Disease Dermatology Psoriasis Atopic Dermatitis Acne Dermatitis Rosacea Acne Vulgaris Pruritus Prurigo Prurigo Nodularis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.09 |
| 52 Week Low | 1.59 |
| Average Volume | 87,027 |
| 200-Day Moving Average | 2.26 |
| 50-Day Moving Average | 2.33 |
| 20-Day Moving Average | 2.87 |
| 10-Day Moving Average | 2.91 |
| Average True Range | 0.19 |
| RSI (14) | 56.14 |
| ADX | 41.78 |
| +DI | 25.73 |
| -DI | 17.43 |
| Chandelier Exit (Long, 3 ATRs) | 2.87 |
| Chandelier Exit (Short, 3 ATRs) | 2.87 |
| Upper Bollinger Bands | 3.25 |
| Lower Bollinger Band | 2.49 |
| Percent B (%b) | 0.43 |
| BandWidth | 26.55 |
| MACD Line | 0.13 |
| MACD Signal Line | 0.20 |
| MACD Histogram | -0.0614 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.01 | ||||
| Resistance 3 (R3) | 3.01 | 2.95 | 2.98 | ||
| Resistance 2 (R2) | 2.95 | 2.90 | 2.95 | 2.97 | |
| Resistance 1 (R1) | 2.89 | 2.87 | 2.86 | 2.88 | 2.96 |
| Pivot Point | 2.82 | 2.82 | 2.81 | 2.82 | 2.82 |
| Support 1 (S1) | 2.76 | 2.77 | 2.73 | 2.76 | 2.68 |
| Support 2 (S2) | 2.70 | 2.74 | 2.69 | 2.67 | |
| Support 3 (S3) | 2.63 | 2.70 | 2.66 | ||
| Support 4 (S4) | 2.63 |
